The use of interleukin-23 inhibitors to treat immune-related psoriasis induced by immune checkpoint inhibitors and in patients with active cancer: A case series and review of the literature

Immune checkpoint inhibitors have revolutionized cancer treatment but can induce immune-related adverse events including psoriasis. Managing immune-related psoriasis or psoriasis in a cancer setting is challenging with a lack of safety data. We describe three patients receiving interleukin-23 inhibi...

Descripción completa

Detalles Bibliográficos
Autores principales: Fournier, Cynthia, Butler, Marcus Otho, Sauder, Maxwell Benjamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
JCMS Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10278391/
https://www.ncbi.nlm.nih.gov/pubmed/37342421
http://dx.doi.org/10.1177/2050313X231181035

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10278391/
https://www.ncbi.nlm.nih.gov/pubmed/37342421
http://dx.doi.org/10.1177/2050313X231181035

Ejemplares similares